Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Alignment Healthcare $256 million secondary offering
We advised the underwriter on the offering
One Call acquisition of Data Dimensions
We are advising One Call on the transaction
Tandem Diabetes Care $300 million convertible senior notes offering
We advised the representatives of the initial purchasers on the offering
Revolution Medicines $1 billion at-the-market offering
We advised the sales agent on the offering
Recursion Pharmaceuticals $300 million at-the-market offering
We advised the sales agent on the offering
Amgen $4 billion notes offering
We advised the bookrunners on the offering
Coloplast acquisition of Uromedica
We are advising Coloplast on the transaction
BioMarin Pharmaceutical $850 million debut senior notes offering
We advised the representative of the initial purchasers
Coherus Oncology $50 million follow-on offering
We advised the joint book-running managers and representatives of the underwriters on the offering
Rhône Capital acquisition of Invacare
We advised Highbridge Capital, as an Invacare secured lender and noteholder, on the transaction